StemCell Therapy

According to a recent press release on Global Regenerative Medicines Market Outlook: Industry Analysis & Opportunity Evaluation 2018-2025 which delivers detailed overview of the global regenerative medicines market in terms of market segmentation by technology, source, application, end-users and region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, trends and regulations & policies.

The Regenerative Medicines industry caters to the individuals with a long-term requirement to treat chronic oncogenic, immunogenic or infectious diseases. Research Nester released a report stating that the market is currently expanding and is expected to grow at a CAGR of 19.33% during the forecast period (2018-2027). By 2027, the global regenerative medicine market is predicted to reach USD 64.32 Billion.

Various funding programs initiated by the International Society for Stem Cell Research in the past as well as in the future are expected to attract large number of potential new players in the regenerative medicines market. Research Grants from organizations such as, Alexander von Humboldt Foundation Sponsorship Programmes, Alliance for Regenerative Rehabilitation and Training Center and Biotechnology, California Institute of Regenerative Medicine (CIRM) and Biological Sciences Research Council (BBSRC) are expected to create higher opportunities for regenerative medicines research and development.

Asia Pacific region is projected to witness enormous growth in forthcoming years. Country governments such as Japan and China across Asia-Pacific are drafting policies to advocate building new infrastructure (and research networks) to push towards a profitable commercialization of regenerative medicine products. Chinese Ministry of Science and Technology (MST),the State of Food and Drug Agency and the Ministry of Health have issued approximately 30 new rules and regulations to increase the development of regenerative medicines across the country. Further, in 2014 Pharmaceutical and Medical Device (PMD) Act and the Safety of Regenerative Medicine Act issued in Japan, new regulations to accelerate the approval process of regenerative medicine products. These initiatives across the countries of Asia-Pacific by the local governments are projected to drive the regenerative medicines market exponentially over the forthcoming years.

To Request a Report Sample for Research Scope CLICK HERE

The global regenerative medicines market is segmented on the basis of technology into gene therapies, cellular therapies, exosome therapeutics and tissue engineering wherein cellular therapies segment is further segmented into cellular immunotherapies, stem cell therapies, therapeutics utilizing, differentiated cell types and direct cell reprogramming.

Growing demand for organ transplantation in developed and developing countries and the commercialization of regenerative medicines are some of the key trends anticipated to supplement the growth of the global regenerative medicine market through the forecast period. Increased use of skin substitutes, grafts, bone matrix and other tissue engineered regenerative medicines are one of the prominent factor backing for the growth of the global regenerative medicine market over the forthcoming years.

The market is further segmented based on the source as autologous and allogeneic. Kite Pharma and Fosun Pharma created joint venture in China to commercialize autologous t-cell therapies to cure cancer in 2019. According to this agreement, Fosun Pharma will deliver the RMB equal of $20 million in financing to sustenance clinical development and engineering activities and kite will provide certain technical transfer facilities to the joint venture. Such ventures in the regenerative medicines market are boosting the autologous segmental growth around the globe.

Despite its innumerable benefits, Regenerative Medicines market is expected to have its own share of challenges and limitations such as the issues of high costs, requirement for highly skilled professionals, and stringent regulatory standards. These are some of the restraining factors that might affect the growth of the market over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global regenerative medicines market which includes company profiling of Smith & Nephew Plc., Sangamo, Integra LifeSciences Corporation, Novartis, Stryker Corporation and other prominent players. In order to expand the market presence, Regenerative Medicines companies are expanding their product line extensively. For an instance, Baxter International announced its participation in The Alliance for Regenerative Medicine (ARM) and the UC San Diego Sanford Stem Cell Clinical Center organized conference for its product upliftment and gaining greater insights into its research and development activities for regenerative medicines.

The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global Regenerative Medicines market that will help industry consultants, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

To request a sample report for Technological Breakthroughs CLICK HERE

About Research Nester:

Research Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives for their future investment while avoiding forthcoming uncertainties. With an out-of-the-box mindset to produce statistical and analytical market research reports, we provide strategic consulting so that our clients can make wise business decisions with clarity while strategizing and planning for their forthcoming needs and succeed in achieving their future endeavors. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds.

Contact for more Info:

AJ Daniel

Email: sales@researchnester.com

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919

Go here to see the original:
Regenerative Medicines - A More Effective and Result Oriented Way to treat chronic Diseases for Long Term Range - PharmiWeb.com

Report Scope: The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries.

New York, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Stem Cell and Regenerative Therapy Market" - https://www.reportlinker.com/p05791357/?utm_source=GNW The current report offers a detailed analysis of the stem cell and regenerative medicines market.

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

The report details market shares of stem cell and regenerative medicines based on products, application, and geography.Based on product the market is segmented into therapeutic products, cell banking, tools and reagents.

The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes: - 28 data tables - An overview of global markets for stem cell and regenerative medicines - Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 - Details of historic background and description of embryonic and adult stem cells - Information on stem cell banking and stem cell research - A look at the growing research & development activities in regenerative medicine - Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals - Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Summary The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018.The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024.

Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

In the global market, North America held the highest market share in 2018.The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period.

The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications.New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future.

The biopharmaceutical companies are investing significantly in cell-based therapeutics.The government organizations are funding research and development activities related to stem cell research.

These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments.The market is impacted through adoption of stem cell therapy.

The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.Read the full report: https://www.reportlinker.com/p05791357/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

More:
Global Stem Cell and Regenerative Therapy Market - Yahoo Finance

NEW YORK, Oct. 21, 2019 /PRNewswire/ --

Regenerative Medicine Market Size, Share & Trends Analysis By Product (Primary Cell-based, Stem & Progenitor Cell-based), By Therapeutic Category (Dermatology, Oncology) And Segment Forecasts, 2019 - 2025

Read the full report: https://www.reportlinker.com/p05807250/?utm_source=PRN

The global regenerative medicine market size is expected to reach USD 5.60 billion by 2025, expanding at a CAGR of 11.6% over the forecast period. Regenerative medicines are expected to have a significant impact in healthcare to treat specific indications and chronic conditions. Therefore, high prevalence of cancer, neurodegenerative, orthopedic, and other aging-associated disorders coupled with increasing global geriatric population is driving the market growth. Moreover, rising prevalence of inheritable genetic diseases is anticipated to fuel the demand in the field of biotechnology field.

Market players are engaged in implementing novel protocols for the release of novel therapeutics. For instance, in July 2018, Convelo Therapeutics launched regenerative medicines for the treatment of various neurological diseases, such as multiple sclerosis.Agreements models initiated by the companies coupled with commercialization in emerging countries fuels the growth. For instance, in March 2018, Hitachi Chemical signed an agreement with the Daiichi Sankyo and SanBio Group to conduct clinical manufacturing of regenerative medicines developed by respective companies for Japanese and U.S. markets.

Regenerative medicine is anticipated to witness great attention in healthcare sector due to its wide range of applications and significant advancements tissue engineering, stem cells, gene therapy, drug discovery, and nanotechnology. For example, 3D printing is preferred over scaffold with stem cells to restore structure and functional characteristics of biological specimens.

Dermatology is estimated to hold the largest market share in terms of revenue in 2018, owing to the availability of various products and their application in simple and chronic wound healing. Oncology therapeutic category on the other hand, is projected to expand at the fastest CAGR during the forecast period owing to the presence of strong pipeline of regenerative medicines for cancer treatment.

North America held the largest regenerative medicine market share in terms of revenue in 2018 and is projected to continue its dominance in near future. A significant number of universities and research organizations investigating various stem cell-based approaches for regenerative apposition in U.S. is anticipated to propel the growth.

Further key findings from the report suggest: Therapeutics emerged dominant among product segments in 2018 due to high usage of primary cell-based therapies along with advances in stem cell and progenitor cell therapies Implementation of primary cell-based therapies in dermatological, musculoskeletal, and dental application results in highest share of this segment Stem cell and progenitor cell-based therapies are anticipated to witness rapid growth due to high investments in stem cell research and increasing number of stem cell banks With rise in R&D and clinical trials, key players are offering consulting services leading to lucrative growth of the services segment Asia Pacific is projected to witness the fastest CAGR during the forecast period due to rapid adoption of cell-based approaches in healthcare and emergence of key players Key players operating in the regenerative medicine market including AstraZeneca; F Hoffmann-La Roche Ltd.; Pfizer Inc.; Merck & Co., Inc.; Integra LifeSciences Corporation; and Eli Lilly and Company

Read the full report: https://www.reportlinker.com/p05807250/?utm_source=PRN

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Read more:
The global regenerative medicine market size is expected to reach USD 5.60 billion by 2025, expanding at a CAGR of 11.6% over the forecast period -...

MIAMI - October 24, 2019 - ( Newswire.com )

The AASCP has recently created guidelines thatare current safety recommendations given to physicians who are using biologics in their medical practice. A highly anticipated and sought after Safety StandardsPanel session, hosted by AASCP on Nov. 2, 2019, will be moderated by The Alliance for Cell Therapy Now,with President Ms. Janet Marchbrody.The sessions normally are closed to the public but this particular SafetyStandard Panel discussion will be open to the public, covering the growing safety concerns of the industry.

Alliance for Cell Therapy Now is a coalition of organizations representing patients, health care providers and the academic and scientific community, who are working together to advance safe and effective regenerative cell therapies. The mission is to advance the development, manufacturing and delivery of safe and effective regenerative cell therapies through policy development, consensus and advocacy. Alliance for Cell Therapy Now is bringing together experts and stakeholders to gain consensus on and advocate for policies that will advance the science and the field, including those focused on promoting clinical research, assuring the adoption of consensus standards to promote safety and quality, building capacity and expertise within the workforce, and establishing a national outcomes database to advance the science, promote improvements in quality and safety, and inform regulatory, paymentand patient decision-making.

Alliance for Cell Therapy Now is guided by an Advisory Board comprised of leaders in the scientific, academicand patient communities; Ms. Janet M. Marchibroda President, Alliance for Cell Therapy Now Fellow, Bipartisan Policy Center Senior Vice President, Health Policy, Bockorny Group, has agreed to join theAASCP as a moderator for their SafetyPanelat The Hyatt Regency in Miami. This particular coveted safetypanel session will be open to the public and broadcast live on YouTube at 3:00 p.m. on Nov. 2, 2019.

According to AASCP, if you are using biologics in your practice, whether you are using SVF, PRP, bone marrow, UCB, amniotic products,exosomes,xenografts, or peptides, there are key considerations to take into account to achieve the best safety for your patients. The AASCP also recommends communication with the Chief Scientific Officer from the laboratory you work with.AASCP advises that just talking to a sales agent is not sufficient enough when determining the quality of products for your patients. Sales agents typically do not have a medical or scientific background.

The spokesman for the AASCP, Dr. AJFarshchian,said earlier: The American Academy of Stem Cell Physicians is a group of physicians, scientists and researchers who collectively represent the most authoritativenon-federal group advocating for guidelines and education on stem cell therapy and regenerative medicine. AASCP members are experts within all fields of stem cell therapy from: SVF, BM, UCB, Exosomes, Peptides, Xenografts, Allografts and Amniotic Fluids and are considered the most experienced leaders for proper advocacy in the field. The AASCP is involved directly with other authorities within the field and seeks only to bring knowledge and awareness for the ever growing regenerative medicine industry.My hope is that the SafetyPanel discussion on Nov.2, 2019, is to help get rid of the bad actors that are damaging the field for everyone.

AASCP is hosting their medical conference in Miami on Nov. 1-3 , 2019. Sessions are normally closed to the public and, therefore, require registration. The conference is taking place at the downtown MiamiHyatt Regency, located at 400 SE 2nd Ave, Miami, FL 33131.Becauseof limited seating, we encourage everyone to please RSVP ataascp.net andto register.

The American Academy of Stem Cell Physicians (AASCP) is an organization created to advance research and the development of therapeutics in regenerative medicine, including diagnosis, treatmentand prevention of disease related to or occurring within the human body. Secondarily, the AASCP aims to serve as an educational resource for physicians, scientistsand the public in diseases that can be caused by physiological dysfunction that areameliorableto medical treatment.

For further information, please contact Marie Barbaat AASCP 305-891-4686 and you can also visit us at http://www.aascp.net.

Related Links AASCP Safety guidelinesAASCP website / registration

Press Release Service by Newswire.com

Original Source: American Academy of Stem Cell Physicians Announced Today That Their Safety Panel Session is Open and Free to the Public

Follow this link:
American Academy of Stem Cell Physicians Announced Today That Their Safety Panel Session is Open and Free to the Public - Valdosta Daily Times

Nerve Repair And Regeneration Market Size, Share & Trends Analysis Report By Surgery (Nerve Grafting, Neurorrhaphy), By Product (Biomaterials Neurostimulation & Neuromodulation Device), And Segment Forecasts, 2019 - 2026

New York, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Nerve Repair And Regeneration Market Size, Share & Trends Analysis Report By Surgery, By Product And Segment Forecasts, 2019 - 2026" - https://www.reportlinker.com/p05807210/?utm_source=GNW

The global nerve repair and regeneration market size is expected to reach USD 17.8 billion by 2026 registering a CAGR of 10.7%. Demand for neurological disorder therapies owing to increasing incidence and rising awareness about the same will drive the market. Moreover, government funding and reimbursement policies and uninterrupted technological advances are also projected to help boost the market growth.

In January 2016, the EU Horizon 2020 program funded a research project Autostem, launched by the NUI Galways Regenerative Medicine Institute (REMEDI), costing about USD 6.73 million. This project was to develop a robotic stem cell production factory, having an edge over the old traditional techniques. This technique offers prospects of new therapies for a range of diseases, such as cancers, diabetes, and arthritis. Increased R&D and investments by key companies in emerging countries are also driving the market growth. In July 2018, the Stem Cells Australia (SCA) received USD 3 million for stem cell research from the Medical Research Future Fund (MRFF).

In addition, government and private funded organizations are conducting clinical trials to develop a safe and effective therapy for different neurological disorders, such as Stem Cells in Umbilical Blood Infusion for Cerebral Palsy (Phase II) and usage of Polyethylene glycol (PEG) drug (Phase I) to promote axonal fusion technique to repair peripheral nerve injuries in humans.

Furthermore, in October 2017, Stryker Corporation acquired VEXIM, a France-based medical device company.VEXIMs portfolio is complementary to Strykers Interventional Spine (IVS) portfolio.

With this acquisition, Stryker will strengthen its distribution channels in Eastern Europe, Middle East, Asia, and Latin America. In January 2018, Boston Scientific Corporation received U.S. FDA approval for the first and only Spectra WaveWriter spinal cord stimulator system. This system is used for paresthesia-based therapy.

Further key findings from the study suggest: In 2018, neuromodulation and neurostimulation devices segment led the market due to increased cases of Central Nervous System (CNS) disorders and awareness about mental disorders and available treatments Biomaterials is anticipated to expand at the fastest CAGR during the forecast period due to technological advancements and development of biodegradable polymers that can help enhance spinal stabilization, healing of fractures, and reduce hospitalization North America led the market in 2018 owing to technological advancements and advent of new devices. Government initiatives and funding and increased cases of injured CNS, such as injuries to the spinal cord and brain, were some of the major reasons responsible for the regions growth Asia Pacific is expected to be the fastest-growing market during the forecast period. Growing geriatric population, technological advancements, and many unmet medical needs are some of the factors driving the regions growth In February 2016, Indian scientists working for Revita Life Sciences were approved to conduct clinical trials in 20 clinically dead patients to bring specific parts of their CNS back to life Combination of therapies including cocktail of peptides, nerve stimulation techniques, injecting the brain with stem cells and other techniques that were successful in bringing patients out of coma were to be used Existing medical devices were combined with regenerative biological medicines with an objective to achieve such a complex initiative Some of the key companies include Boston Scientific, Inc.; Stryker Corporation; St. Jude Medical, Inc.; Medtronic plc.; Baxter International, Inc.; AxoGen, Inc.; Polyganics B.V.; Integra; Cyberonics, Inc.; and Lifesciences CorporationRead the full report: https://www.reportlinker.com/p05807210/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Follow this link:
The global nerve repair and regeneration market size is expected to reach USD 17.8 billion by 2026 registering a CAGR of 10.7% - Yahoo Finance

NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced, Chaim Lebovits, President and CEO, will serve as a Keynote Speaker at Cell Series UK.Cell Series UK, will be held October 29-30, 2019, at London Novotel West, London, UK. The Conference, organized by Oxford Global, is one of the foremost events in Europe focused on regenerative medicine and cellular innovation.

Ralph Kern MD, MHSc, Chief Operating and Chief Medical Officer of Brainstorm, who will also participate at Cell Series UK stated, We are very pleased to have Chaim Lebovits presenting at this prestigious conference where global leaders in stem cell and regenerative medicine will have the opportunity to learn more about NurOwn and the critical research being conducted by the Company. Mr. Lebovits Keynote Address, Stem Cell Therapeutic Approaches For ALS, will be presented to leading members of the scientific and business community including potential partners and investors.

About NurOwnNurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

AboutBrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn Cellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm received U.S. FDA clearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) in December 2018 and has been enrolling clinical trial participants since March 2019. For more information, visit the company's website.

Safe-Harbor Statements Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PR Phone: +1.646.677.1839sean.leous@icrinc.com

See the original post here:
BrainStorm Cell Therapeutics' President and CEO to be Featured as Keynote Speaker at Cell Series UK 2019 - GlobeNewswire

The build-out is estimated at $9.5M.

United Therapeutics received a building permit Tuesday for a $9.5M build-out of its cell therapy facility on the second floor of Mayo Clinics Discovery and Innovation Building.

The 21,843-square-foot space will house an automated stem cell manufacturing site, which is one of the first of its kind in the country. The Whiting-Turner Contracting Co. is the project contractor.

The technology, approved by the FDA in 2018, allows the Mayo Clinic Center for Regenerative Medicine to produce cells from the bone marrow of a stem cell donor in large enough quantities to be used as treatments in clinical trials. It allows for the treatment of multiple patients at the same time.

Construction began in 2017 on the $32.4M building at 14221 Kendall Hench Drive. It held a grand opening in August.

The first floor houses three ex-vivo lung perfusion surgical suites used for lung restoration, another form of regenerative medicine. It turns donor lungs, which previously would have previously been unusable, into viable transplant organs. United Therapeutics also collaborates with Mayo Clinic on lung restoration.

The third floor houses the Life Sciences Incubator for biotech entrepreneurs, which offers coworking space, wet labs, business resources, networking and entrepreneurial training.

Read more:
United Therapeutics Receives Permit For Cell Therapy Facility Build-Out At Mayo - Pharmaceutical Online

Thought regenerating tissue was just for salamanders? It turns out that humans can regenerate certain tissues faster than others too.

A study authored by Duke researchers found that humans have the ability to regenerate cartilage in certain joints, though some are faster than others. These findings could potentially lead to new treatments for osteoarthritis, one of the worlds most common diseases.

The study, which included research going back more than a decade, outlined the discovery of an age gradient for different types of cartilage in humans. The researchers examined protein modifications and discovered that ankle cartilage had a higher rate of production than cartilage in the knees or hips.

That was a big surprise because most people think that all cartilage is the samesame proteins, same everything, said Professor of Medicine Virginia Kraus, the senior author of the study. We expected to be able to see a different turnover of different proteins, but the fact that it was changing by location, that was really surprising.

To contextualize these findings, Kraus and Ming-Feng Hsueh, a medical instructor in the department of orthopedic surgery and the studys lead author, went back millions of years to the evolution of a small lizard-like amphibian: the salamander. Salamanders are noteworthy in the animal kingdom due to their ability to completely regenerate lost limbsan ability that is shared by only a few other animals, such as zebrafish.

A study published in 2016 found that salamanders, zebrafish and another limb-regenerating type of freshwater fishall of which were separated by millions of years of evolutionhad essentially the same mechanisms for joint repair.

These mechanisms worked more effectively in repairing the parts of limbs that were closer to the torso compared to those that were farther away. This was a direct parallel to humans seemingly being able to repair cartilage in ankles much faster and more easily than in hips.

To Kraus and Hsueh, this signified that these regeneration mechanisms could be the same ones present in humans. This hypothesis was further bolstered by reports of children who could regenerate the distal parts of their fingertips. However, researchers dont know why or how this ability is turned off.

Limb regeneration is highly complex, Kraus said. Just looking back at [salamanders and zebrafish] with a fresh eye and trying to say, What is it about that process that we either share or we dont share? is how maybe we might be able to gain insights into what is lacking [in humans].

In fact, they found that this innate regenerative capability likely does exist in people.

From our study, we think that humans still have the ability [to regenerate limbs] or at least repair them to some level, Hsueh said. We think that the key factors to doing this are either missing or insufficient in humans. Our strategy for the future is to try to find the key factors that humans do not have enough of.

The factors that regulate the process of joint repair are known as microRNA. Hsueh explained that the answer to increasing repairability in joints afflicted by osteoarthritis is locating the microRNA that is in high abundance in ankles and increasing its level in other joints, such as the hip.

Signup for our editorially curated, weekly newsletter. Cancel at any time.

However, beyond increasing the amount of beneficial microRNA, Kraus and Hseuh also noted that it is necessary to identify and turn off bad microRNA, which may inhibit collagen production and thus aggravate osteoarthritis. Just like every other system in the body, joint repair is about balance.

This study may lead to new ways of treating osteoarthritis, which occurs when the cartilage at the ends of bones wears down. It can cause severe joint pain, swelling and stiffness, and currently affects an estimated 27 million Americans as of 2018.

Kraus said that unlike rheumatoid arthritis, which has treatments to prevent the disease as well as put it into remission, there are currently no existing effective treatments for osteoarthritis.

Contrary to popular belief, osteoarthritis isnt just a geriatric disease.

We know that 50% of people who get an anterior cruciate ligament tear will get osteoarthritis at a young age. So any time I watch the Duke basketball team and somebody goes down, Im like this is terrible, Kraus said. They have a one in two chance of developing osteoarthritis in just a few years.

Kraus and Hsuehs short-term goal is to help boost cartilage repair in patients with osteoarthritis, sports injuries and amputated limbs. In the long term, they hope to eradicate osteoarthritis entirely.

I think [in 50 years] well be in an enviable position in the way rheumatoid arthritis is thought of now, Kraus said. I think therell be early identification, well have really robust treatments, [and] joint replacements will be rare. I think well treat joint injuries very seriously the way heart attacks are treatedimmediately, with something really effective.

The researchers said funding is the biggest problem going forward. Most of the support for the study came from the National Institutes of Health, but according to Hsueh, who has been working on the study since he was a graduate student, obtaining grants is constantly an uphill battle.

Its breaking new ground and its really hard to get old thinking to change, Kraus said. Its a hard sell.

Kraus and Hsueh believe there is much work that can be done outside the field of rheumatology and orthopedics to contribute to these advancements, including collaborating with developmental scientists, experts in salamanders and specialists in regenerative medicine.

By putting the right brains together so that theres more crosstalk, that would really facilitate the advancements, Kraus said. Thats the future.

Originally posted here:
Regeneration race: Cartilage regrows faster in some joints than others - Duke Chronicle

Orthopedic surgeon and hand specialist Dr. Scott Zimmer will talk issues experienced with arthritis and ways to stop arthritis pain in an event titled, Arthritis: From the Fingertip to the Shoulder, the Latest Innovations in Arthritis Treatment, 6 p.m. Oct. 30 at 25501 Chagrin Boulevard in Beachwood.

Zimmer will discuss what arthritis is, how it affects the joints, methods to control arthritis pain at home, nonsurgical methods of easing pain if home methods stop working, including regenerative medicine and surgical methods.

Zimmer is the founder of Ohio Hand to Shoulder Center and a member of the Lake Health physician group. He also serves as department chair of hand and upper extremity surgery and vice president of medical staff at Lake Beachwood Medical Center. He previously directed the hand and upper extremity center for UH Geauga Medical Center for 10 years.

Light refreshments will be served.

Space is limited. To RSVP, call 800-454-9800 or visit tinyurl.com/Drzimmertalk.

Read the original here:
Dr. Scott Zimmer to speak about arthritis - Cleveland Jewish News

Stem cell therapy for animals has seen breakthroughs

Stem cell therapy is increasingly becoming a more mainstream form of medicine. Usually applied to humans, the use of this regenerative treatment is now also being extended to animals including cats and dogs. Regenerative medicine, particularly stem cell treatment has seen many advancements in recent years with some groundbreaking studies coming to light.

Taking the cells from bone marrow, umbilical cords, blood or fat, stem cells can grow to become any kind of cell and the treatment has seen many successes in animals. The regenerative therapy has been useful particularly for treatment of spinal cord and bone injuries as well as problems with tendons, ligaments and joints.

Expanded Potential Stem Cells (EPSCs) have been obtained from pig embryos for the first time. The cells offer groundbreaking potential for studying embryonic development and producing transnational research in genomics and regenerative medicine, biotechnology and agriculture.

The cells have been efficiently derived from pig preimplantation embryos and a new culture medium developed in Hong Kong and Cambridge enabled researchers from the FLI to establish permanent embryonic stem cell lines. The cells have been discovered in a collaboration between research groups from the Institute of Farm Animal Genetics at the Friedrich-Loeffler-Institut (FLI) in Mariensee, Germany, the Wellcome Trust Sanger Institute in Cambridge, UK and the University of Hong Kong, Li Ka Shing Faculty of Medicine, School of Biomedical Sciences.

Embryonic stem cells (ESC) are derived from the inner cells of very early embryos, the so-called blastocysts. Embryonic stem cells are all-rounders and can develop into various cell types of the body in the culture dish. This characteristic is called pluripotency. Previous attempts to establish pluripotent embryonic stem cell lines from farm animals such as pigs or cattle have resulted in cell lines that have not really fulfilled all properties of pluripotency and were therefore called ES-like.

Dr Monika Nowak-Imialek of the FLI said: Our porcine EPSCs isolated from pig embryos are the first well-characterized cell lines worldwide. EPSCs great potential to develop into any type of cell provides important implications for developmental biology, regenerative medicine, organ transplantation, disease modelling and screening for drugs.

The stem cells can renew themselves meaning they can be kept in culture indefinitely, and also show the typical morphology and gene expression patterns of embryonic stem cells. Somatic cells have a limited lifespan, so these new stem cells are much better suited for long selection processes. It has been shown that these porcine stem cell lines can easily be modified with new genome editing techniques such as CRISPR/Cas, which is particularly interesting for the generation of porcine disease models.

The EPSCs have a high capacity to develop not only into numerous cell types of the organism, but also into extraembryonic tissue, the trophoblasts, making them very unique and lending them their name. This capacity could prove valuable for the future promising organoid technology, where organ-like small cell aggregations are grown in 3D aggregates that can be used for research into early embryo development, various disease models and testing of new drugs in petri dishes. In addition, the authors were able to show that trophoblast stem cells can be generated from their porcine stem cells, offering a unique possibility to investigate functions or diseases of the placenta in vitro.

A major hurdle to using neural stem cells derived from genetically different donors to replace damaged or destroyed tissues, such as in a spinal cord injury, has been the persistent rejection of the introduced material (cells), necessitating the use of complex drugs and techniques to suppress the hosts immune response.

Earlier this year, an international team led by scientists at University of California San Diego School of Medicine successfully grafted induced pluripotent stem cell (iPSC)-derived neural precursor cells back into the spinal cords of genetically identical adult pigs with no immunosuppression efforts. The grafted cells survived long-term, displayed differentiated functionality and caused no tumours.

The researchers also demonstrated that the same cells showed similar long-term survival in adult pigs with different genetic backgrounds after only short course use of immunosuppressive treatment once injected into injured spinal cord.

Senior author of the paper Martin Marsala, MD, professor in the Department of Anesthesiology at UC San Diego School of Medicine said: The promise of iPSCs is huge, but so too have been the challenges. In this study, weve demonstrated an alternate approach.

We took skin cells from an adult pig, an animal species with strong similarities to humans in spinal cord and central nervous system anatomy and function, reprogrammed them back to stem cells, then induced them to become neural precursor cells (NPCs), destined to become nerve cells. Because they are syngeneic genetically identical with the cell-graft recipient pig they are immunologically compatible. They grow and differentiate with no immunosuppression required.

Co-author Samuel Pfaff, PhD, professor and Howard Hughes Medical Institute Investigator at Salk Institute for Biological Studies, said: Using RNA sequencing and innovative bioinformatic methods to deconvolute the RNAs species-of-origin, the research team demonstrated that pig iPSC-derived neural precursors safely acquire the genetic characteristics of mature CNS tissue even after transplantation into rat brains.

NPCs were grafted into the spinal cords of syngeneic non-injured pigs with no immunosuppression finding that the cells survived and differentiated into neurons and supporting glial cells at all observed time points. The grafted neurons were detected functioning seven months after transplantation.

Then researchers grafted NPCs into genetically dissimilar pigs with chronic spinal cord injuries, followed by a transient four-week regimen of immunosuppression drugs again finding long-term cell survival and maturation.

Marsala continued: Our current experiments are focusing on generation and testing of clinical grade human iPSCs, which is the ultimate source of cells to be used in future clinical trials for treatment of spinal cord and central nervous system injuries in a syngeneic or allogeneic setting.

Because long-term post-grafting periods between one and two years are required to achieve a full grafted cells-induced treatment effect, the elimination of immunosuppressive treatment will substantially increase our chances in achieving more robust functional improvement in spinal trauma patients receiving iPSC-derived NPCs.

In our current clinical cell-replacement trials, immunosuppression is required to achieve the survival of allogeneic cell grafts. The elimination of immunosuppression requirement by using syngeneic cell grafts would represent a major step forward said co-author Joseph Ciacci, MD, a neurosurgeon at UC San Diego Health and professor of surgery at UC San Diego School of Medicine.

Other recent advancements include the advancement toward having a long-lasting repair caulk for blood vessels. A new method has been for generating endothelial cells, which make up the lining of blood vessels, from human induced pluripotent stem cells. When endothelial cells are surrounded by a supportive gel and implanted into mice with damaged blood vessels, they become part of the animals blood vessels, surviving for more than 10 months.

The research was carried out by stem cell researchers at Emory University School of Medicine and could form the basis of a treatment for peripheral artery disease, derived from a patients own cells.

Young-sup Yoon, MD, PhD, who led the team, said: We tried several different gels before finding the best one. This is the part that is my dream come true: the endothelial cells are really contributing to endogenous vessels.

When cells are implanted on their own, many of them die quickly, and the main therapeutic benefits are from growth factors they secrete. When these endothelial cells are delivered in a gel, they are protected. It takes several weeks for most of them to migrate to vessels and incorporate into them.

Other groups had done this type of thing before, but the main point is that all of the culture components we used would be compatible with clinical applications.

This research is particularly successful as previous attempts to achieve the same effect elsewhere had implanted cells lasting only a few days to weeks, using mostly adult stem cells, such as mesenchymal stem cells or endothelial progenitor cells. The scientists also designed a gel to mimic the supportive effects of the extracellular matrix. When encapsulated by the gel, cells could survive oxidative stress inflicted by hydrogen peroxide that killed unprotected cells. The gel is biodegradable, disappearing over the course of several weeks.

The scientists tested the effects of the encapsulated cells by injecting them into mice with hindlimb ischemia (restricted blood flow in the leg), a model of peripheral artery disease.

After 4 weeks, the density of blood vessels was highest in mice implanted with gel-encapsulated endothelial cells. The mice were nude, meaning genetically immunodeficient, facilitating acceptance of human cells.

The scientists found that implanted cells produce pro-angiogenic and vasculogenic growth factors. In addition, protection by the gel augmented and prolonged the cells ability to contribute directly to blood vessels. To visualise the implanted cells, they were labelled beforehand with a red dye, while functioning blood vessels were labelled by infusing a green dye into living animals. Implanted cells incorporated into vessels, with the highest degree of incorporation occurring at 10 months.

Continue reading here:
Stem cell therapy is for animals too - SciTech Europa

Regenerative Medicine Market: Snapshot

Regenerative medicine is a part of translational research in the fields of molecular biology and tissue engineering. This type of medicine involves replacing and regenerating human cells, organs, and tissues with the help of specific processes. Doing this may involve a partial or complete reengineering of human cells so that they start to function normally.

Order Brochure for more Detailed Information @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1889

Regenerative medicine also involves the attempts to grow tissues and organs in a laboratory environment, wherein they can be put in a body that cannot heal a particular part. Such implants are mainly preferred to be derived from the patients own tissues and cells, particularly stem cells. Looking at the promising nature of stem cells to heal and regenerative various parts of the body, this field is certainly expected to see a bright future. Doing this can help avoid opting for organ donation, thus saving costs. Some healthcare centers might showcase a shortage of organ donations, and this is where tissues regenerated using patients own cells are highly helpful.

There are several source materials from which regeneration can be facilitated. Extracellular matrix materials are commonly used source substances all over the globe. They are mainly used for reconstructive surgery, chronic wound healing, and orthopedic surgeries. In recent times, these materials have also been used in heart surgeries, specifically aimed at repairing damaged portions.

Cells derived from the umbilical cord also have the potential to be used as source material for bringing about regeneration in a patient. A vast research has also been conducted in this context. Treatment of diabetes, organ failure, and other chronic diseases is highly possible by using cord blood cells. Apart from these cells, Whartons jelly and cord lining have also been shortlisted as possible sources for mesenchymal stem cells. Extensive research has conducted to study how these cells can be used to treat lung diseases, lung injury, leukemia, liver diseases, diabetes, and immunity-based disorders, among others.

Global Regenerative Medicine Market: Overview

The global market for regenerative medicine market is expected to grow at a significant pace throughout the forecast period. The rising preference of patients for personalized medicines and the advancements in technology are estimated to accelerate the growth of the global regenerative medicine market in the next few years. As a result, this market is likely to witness a healthy growth and attract a large number of players in the next few years. The development of novel regenerative medicine is estimated to benefit the key players and supplement the markets growth in the near future.

Request TOC for Facts & Tables @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1889

Global Regenerative Medicine Market: Key Trends

The rising prevalence of chronic diseases and the rising focus on cell therapy products are the key factors that are estimated to fuel the growth of the global regenerative medicine market in the next few years. In addition, the increasing funding by government bodies and development of new and innovative products are anticipated to supplement the growth of the overall market in the next few years.

On the flip side, the ethical challenges in the stem cell research are likely to restrict the growth of the global regenerative medicine market throughout the forecast period. In addition, the stringent regulatory rules and regulations are predicted to impact the approvals of new products, thus hampering the growth of the overall market in the near future.

Global Regenerative Medicine Market: Market Potential

The growing demand for organ transplantation across the globe is anticipated to boost the demand for regenerative medicines in the next few years. In addition, the rapid growth in the geriatric population and the significant rise in the global healthcare expenditure is predicted to encourage the growth of the market. The presence of a strong pipeline is likely to contribute towards the markets growth in the near future.

Global Regenerative Medicine Market: Regional Outlook

In the past few years, North America led the global regenerative medicine market and is likely to remain in the topmost position throughout the forecast period. This region is expected to account for a massive share of the global market, owing to the rising prevalence of cancer, cardiac diseases, and autoimmunity. In addition, the rising demand for regenerative medicines from the U.S. and the rising government funding are some of the other key aspects that are likely to fuel the growth of the North America market in the near future.

Furthermore, Asia Pacific is expected to register a substantial growth rate in the next few years. The high growth of this region can be attributed to the availability of funding for research and the development of research centers. In addition, the increasing contribution from India, China, and Japan is likely to supplement the growth of the market in the near future.

Avail the Discount on this Report @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1889

Global Regenerative Medicine Market: Competitive Analysis

The global market for regenerative medicines is extremely fragmented and competitive in nature, thanks to the presence of a large number of players operating in it. In order to gain a competitive edge in the global market, the key players in the market are focusing on technological developments and research and development activities. In addition, the rising number of mergers and acquisitions and collaborations is likely to benefit the prominent players in the market and encourage the overall growth in the next few years.

Some of the key players operating in the regenerative medicine market across the globe are Vericel Corporation, Japan Tissue Engineering Co., Ltd., Stryker Corporation, Acelity L.P. Inc. (KCI Licensing), Organogenesis Inc., Medtronic PLC, Cook Biotech Incorporated, Osiris Therapeutics, Inc., Integra Lifesciences Corporation, and Nuvasive, Inc. A large number of players are anticipated to enter the global market throughout the forecast period.

Excerpt from:
Regenerative Medicine Market Industry Outlook, Growth Prospects and Key Opportunities - Health News Office

NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced that it will be presenting at the Dawson James Securities 5th Annual Small Cap Growth Conference, being held on October 28-29, 2019 at the Wyndham Grand Hotel in Jupiter, Florida.

Preetam Shah, PhD, MBA, Chief Financial Officer is scheduled to present on Tuesday, October 29th at 3:40 p.m. Eastern Time, in Track 2 - Preserve Ballroom B, with one-on-one meetings to be held throughout the conference.

Chaim Lebovits, President and CEO of BrainStorm said, We are pleased to have the opportunity to have Dr. Shah present at the Dawson James Small Cap Growth Conference. Dr. Shah, joined BrainStorm in September 2019, and we look forward to having him present the Companys growth strategy and future to a wide audience of accreditied investors.

About NurOwn NurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

AboutBrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn Cellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm received U.S. FDA clearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) in December 2018 and has been enrolling clinical trial participants since March 2019. For more information, visit the company's website.

Safe-Harbor Statements Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PR Phone: +1.646.677.1839sean.leous@icrinc.com

Follow this link:
BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference - GlobeNewswire

Cotton candy is a staple of every carnival.Since 1904, children and adults alike have been entranced by the unique spinning process that conjures upbig sugar clouds seemingly out of nowhere.

Scientists are now using this concept to improve lab-grown meat in its mouthfeel and taste to better resemblemeat.

The technique researchers at the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) are using is known as immersion Rotary Jet-Spinning (iRJS). It uses centrifugal force to spin long nanofibers of specific shapes and sizes much like when making cotton candy.

Thus far, they have grown rabbit and cow muscles on edible gelatin scaffolds that resemble the texture and consistency of meat, illustrating that realistic meat products may be an eventuality, sans the need to rear and butcher animals.

All this began after Kit Parker, the Tarr Family Professor of Bioengineering and Applied Physics at SEAS and senior author of the study, was a competition show judge on the Food Network.

"The materials science expertise of the chefs was impressive," said Parker. "After discussions with them, I began to wonder if we could apply all that we knew about regenerative medicine to the design of synthetic foods. After all, everything we have learned about building organs and tissues for regenerative medicine applies to food: healthy cells and healthy scaffolds are the building substrates, the design rules are the same, and the goals are the same: human health. This is our first effort to bring hardcore engineering design and scalable manufacturing to the creation of food."

The hardest thing about bioengineering meat is reproducing the skeletal muscle and fat tissue characteristic of animal meat, which grow in long, thin fibers -- as seen in the grain of a steak or the strings that come apart when shredding pork or chicken.

"Muscle cells are adherent cell types, meaning they need something to hold onto as they grow," said Luke Macqueen, first author of the study and postdoctoral fellow at SEAS and the Wyss Institute for Bioinspired Engineering. "To grow muscle tissues that resembled meat, we needed to find a 'scaffold' material that was edible and allowed muscle cells to attach and grow in 3D. It was important to find an efficient way to produce large amounts of these scaffolds to justify their potential use in food production."

The lab-grown meat has beenmechanically tested for comparisonalongside real rabbit, bacon, beef tenderloin, prosciutto and other meat products. Although their goal may not be as simple as spinning cotton candy, the researchers have shown that fully lab-grown meat is a possibility.

(This article was edited to correct somefactual errors)

Read the rest here:
The Key To Improving Lab-Grown Meat: Cotton Candy - International Business Times

24 October 2019

Most cancers kill because tumour cells spread, or metastasise beyond the primary site, for example breast, to invade other organs, brain being one. Now, a University of Southern California (USC), study has found that circulating tumour cells can actually target specific distant organs.

Their study of brain-invading breast cancer reveals that circulating tumour cells have a molecular signature indicating specific organ preferences.

The findings, which appear in Cancer Discovery, explain how tumour cells in the blood target a particular organ and may enable the development of treatments to prevent the spread of these metastatic cancers.

In this study breast cancer cells from the blood of breast cancer patients with metastatic tumours were isolated, expanded and grown in the lab.

Analysis of these cells identified regulator genes and proteins within the cells that apparently directed the cancers spread to the brain. The team were therefore able to predict that a patients breast cancer cells would eventually migrate to the brain.

Assistant professor of stem cell and regenerative medicine at the Keck School of Medicine at USC, Min Yu, also discovered that a protein on the surface of these brain-targeting tumour cells helps them to breech the blood brain barrier and lodge in brain tissue, while another protein inside the cells shield them from the brains immune response, enabling them to grow there.

We can imagine someday using the information carried by circulating tumour cells to improve the detection, monitoring and treatment of the spreading cancers, Yu said.

Related reading:

If you found this story interesting or helpful,sign up to our weekly e-newsand keep up to date with all the latest from Brain Tumour Research.

Here is the original post:
Progress toward improving detection, monitoring and treatment of metastatic cancers - Brain Tumour Research

publication date: Oct. 18, 2019

The UCLA Jonsson Comprehensine Cancer Center has launched a CAR T-cell immunotherapy trialthat will attack cancer cells by simultaneously recognizing two targetsCD19 and CD20that are expressed on B-cell lymphoma and leukemia.

By launching a bilateral attack instead of using the conventional single-target approach, researchers are hoping to minimize resistance and increase the life expectancy for people diagnosed with these cancers.

One of the reasons CAR T cell therapy can stop working in patients is because the cancer cells escape from therapy by losing the antigen CD19, which is what the CAR T cells are engineered to target, Sarah Larson, a health sciences clinical instructor in hematology/oncology at UCLA Health and the principal investigator on the trial, said in a statement One way to keep the CAR T cells working is to have more than one antigen to target. So, by using both CD19 and CD20, the thought is that it will be more effective and prevent the loss of the antigen, which is known as antigen escape, one of the common mechanisms of resistance.

Up to two-thirds of the patients who experience relapse after being treated with the FDA-approved CD19 CAR T-cell therapy develop tumors that have lost CD19 expression. UCLA researchers are identifying and testing new strategies like this one so many more patients can benefit from the therapy.

In preclinical studiesled byYvonne Chen, an associate professor of microbiology, immunology, and molecular genetics at UCLA and the sponsor of the trial, the team was able to show that by simultaneously attacking two targets, the engineered T cells developed in her lab could achieve a much more robust defense compared to conventional, single-target CAR T cells against tumors in mice.

Chens team designed the CARs based on the molecular understanding of the CARs architecture, the antigen structure and the CAR/antigen binding interaction to achieve optimal T cell function. This design helps the T cells have dual-antigen recognition to help prevent antigen escape.

Based on these results, were quite optimistic that the bispecific CAR can achieve therapeutic improvement over the single-input CD19 CAR thats currently available, said Chen, who is also the co-director of the Jonsson Cancer Centers Tumor Immunology Program and a member of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research.

This first-in-humans study will evaluate the therapy in patients with non-Hodgkins B-cell lymphoma or chronic lymphocytic leukemia that has come back or has not responded to treatment. The goal is to determine a safe therapeutic dose.

Patients enrolled in the trial will have their white blood cells (T cells) collected intravenously then reengineered in the laboratory so the T cells can produce tumor-specific receptors (CARs), which allow the T cells to recognize and attack the CD19 and CD20 proteins on the surface of tumor cells. The new smarter and stronger T cells are then infused back into the patient and primed to recognize and kill cancer cells.

The trial is currently only offered at UCLA.

Results from STELLAR trial in MPM published in The Lancet Oncology

Novocure said the results from the STELLAR trial were published inThe Lancet Oncology.

The STELLAR trial was a prospective, single-arm trial including 80 patients that studied the use of Tumor Treating Fields, delivered via the NovoTTF-100L System, in combination with pemetrexed plus cisplatin/carboplatin as a first-line treatment for patients with unresectable, locally advanced or metastatic malignant pleural mesothelioma.

Data showed a median overall survival of 18.2 months (95 percent CI, 12.1 months-25.8 months) for patients treated with NovoTTF-100L and pemetrexed plus cisplatin or carboplatin. One- and two-year survival rates were 62.2 percent (95 percent CI, 50.3 percent-72.0 percent) and 41.9 percent (95 percent CI, 28.0 percent-55.2 percent), respectively. No serious systemic adverse events were considered to be related to the use of NovoTTF-100L. The most common mild to moderate adverse event was skin irritation beneath the transducer arrays.

The STELLAR trial demonstrated encouraging overall survival results with no increase in systemic toxicity observed in MPM patients treated with Tumor Treating Fields and standard chemotherapy, Giovanni Luca Ceresoli, head of pulmonary oncology at the Humanitas Gavazzeni Hospital in Bergamo, Italy, and principal investigator in the STELLAR trial, said in a statement. The median overall survival of 18.2 months is impressive given that MPM is a tumor with a dismal prognosis and few effective therapeutic options.

Median progression free survival was 7.6 months (95 percent CI, 6.7 percent-8.6 percent) for patients treated with NovoTTF-100L and pemetrexed plus cisplatin or carboplatin. There was a 97 percent disease control rate in patients with at least one follow-up CT scan performed (n=72). 40 percent of patients had a partial response, 57 percent had stable disease and 3 percent had progressive disease.

IASLC invites comments on Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens Following Neoadjuvant Therapy

The International Association for the Study of Lung Cancer announced an open comment period for the IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens Following Neoadjuvant Therapy paper.

The paper has been made available hereto provide an opportunity for public review of new draft recommendations. The open comment period runs from Oct. 14 to Nov. 7.

With the recent growing number of neoadjuvant therapy clinical trials for non-small cell lung cancer, there is a great need for standardization of specimen processing since major pathologic response has consistently been shown to be an important prognostic indicator.

The purpose of the paper is to outline detailed recommendations on how to process lung cancer resection specimens and to define pathologic complete response including major pathologic response and pathologic complete response following neoadjuvant therapy.

Currently there is no established guidance on how to process and evaluate resected lung cancer specimens following neoadjuvant therapy in the setting of clinical trials and clinical practice, Giorgio Scagliotti, past president of the IASLC and co-author of the paper, said in a statement. There is also a lack of precise definitions on the degree of pathologic response, including MPR or pCR.

IASLC is making an effort to collect such data from existing and future clinical trials. These recommendations are intended as guidance for clinical trials, although it is hoped they can be viewed as suggestions for good clinical practice outside of clinical trials, to improve consistency of pathologic assessment of treatment response.

The recommendations were developed by the IASLC Pathology Committee in collaboration with an international multidisciplinary group of experts in medical oncology, thoracic surgery and radiology.

We are crossing an exciting period of preclinical and clinical research around thoracic oncology. Targeted therapies and immunotherapy have greatly improved survival expectations in advanced disease and we believe they can equally generate benefit in the systemic therapy of earlier stages of the disease, Scagliotti said in a statement. Our initiative aims to use rigorous experimental conditions to analyze tissue specimens, collected in the context of already performed or ongoing neoadjuvant studies with targeted therapies and immunotherapy, to generate a diagnostic algorithm to be used in all subsequent studies in order to accelerate the scientific information about the clinical benefit produced by the neoadjuvant approach.

Expert second opinion improves reliability of melanoma diagnoses

Getting a reliable diagnosis of melanoma can be a significant challenge for pathologists.The diagnosis relies on a pathologists visual assessment of biopsy material on microscopic slides, which can often be subjective.

Of all pathology fields, analyzing biopsies for skin lesions and cancers has one of the highest rates of diagnostic errors, which can affect millions of people each year.

Now, a study led by UCLA researchers, has found that obtaining a second opinion from pathologists who are board certified or have fellowship training in dermatopathology can help improve the accuracy and reliability of diagnosing melanoma, one of the deadliest and most aggressive forms of skin cancer.

A diagnosis is the building block on which all other medical treatment is based,Joann Elmore, a professor of medicine at the David Geffen School of Medicine at UCLA and researcher at the UCLA Jonsson Comprehensive Cancer Center, said in a statement.All patients deserve an accurate diagnosis. Unfortunately the evaluation and diagnosis of skin biopsy specimens is challenging with a lot of variability among physicians.

In the study, led by Elmore and colleagues, the value of a second opinion by general pathologists and dermatopathologists were evaluated to see if it helped improve thecorrect diagnostic classification.

To evaluate the impact of obtaining second opinions, the team used samples from the Melanoma Pathology Study, which comprises of 240 skin biopsy lesion samples. Among the 187 pathologists who examined the cases, 113 were general pathologists and 74 were dermatopathologists.

The team studied misclassification rates, which is how often the diagnoses of practicing US pathologists disagreed with a consensus reference diagnosis of three pathologists who had extensive experience in evaluating melanocytic lesions. The team found that the misclassification of these lesions yielded the lowest rates when first, second and third reviewers were sub-specialty trained dermatopathologists. Misclassification was the highest when reviewers were all general pathologists who lacked the subspecialty training.

Our results show having a second opinion by an expert with subspecialty training provides value in improving theaccuracy of thediagnosis, which is imperative to helpguide patients to the most effective treatments, said Elmore, whois also the director of the UCLA National Clinician Scholars Program.

Elmore is now studying the potential impact of computer machine learning as a tool to improve diagnostic accuracy. She is partnering with computer scientists who specialize in computer visualization of complex image information, as well as leading pathologists around the globe to develop an artificial intelligence (AI)-based diagnostic system.

Michael Piepkorn of the University of Washington School of Medicine is the studys first author. Raymond Barnhill of the Institut Curie is the co-senior author.

The study was published in JAMA Network Open and supported by NCI.

Go here to read the rest:
UCLA opens CAR T-cell trial focused on the most common types of lymphoma, leukemia - The Cancer Letter Publications

Regenerative Medicine research is poised to change the way we know health care. This cutting-edge technology demands new tools and solutions that are able to keep up with the development in personalised medicine. Texture Analysis, which has long been used by the pharmaceutical, food and cosmetic industries, is increasingly being used to evaluate properties of medical devices.

Texture Analysis refers to calculating properties such as firmness, adhesiveness, compressive strength, swelling/absorption, in addition to relaxation behaviour, fatigue and brittleness. Regulatory agencies, including the FDA, have used the TA.XTplus Texture Analyser to evaluate medical devices. In addition, the patent literature increasingly relies on texture analysis to validate claims.

In its most basic configuration, the instrument carries loadcells ranging from 500 g to 750 kg which provide the force measurement for compression or tensile testing of samples. The arm of the instrument moves up or down at speeds from 0.01-40 mm/s collecting data at very precise resolution at up to 2000 points per second.

The mechanical function of medical devices and engineered tissues is a primary endpoint for the successful regeneration of many biological tissues. It is critical that the mechanical function be characterised and compared to initial benchmark function to determine quality control standards for the next generation of health care.

The metered-dose inhaler (MDI) delivers a precise, reproducible dose of drug accurately to the deep lung. It is also well accepted by patients who depend on MDIs in their treatment and therefore it is essential to constantly improve this technology. Patients need to rely on their inhaler to provide them with the required medication which is often at a crucial time when physical strength may be very low.

The metering valve, whose performance is assessed with this test, is a critical component of a finished metered-dose inhaler. The interaction between the elastomeric components and the formulation can significantly affect product performance. A change in formulation, for example implementing a new propellant system, may necessitate a complete redesign of the valve system in order to successfully deliver the drug with the minimum of difficulty.

The Inhaler Support Rig provides a holding device for the inhaler so that it can be tested with a hemispherical probe which best mimics the action of the finger for drug delivery. The force required to push down on the inhaler to deliver the drug is measured. This assesses the performance of the metering valve.

Metered Dose Inhaler test and typical comparative graphs

An assessment of syringeability is required to assess the potential effects of formulations and their subsequent mechanical consequences to reach an optimal performance. The syringeability of each formulation is determined using a Universal Syringe Rig on a Texture Analyser. This innovative attachment effectively measures the aspiration and extraction forces of syringe pistons. The extraction force quantifies how easily the injectable material is expressed during syringe depression and material discharge. This measured force impacts patient comfort during injection and affects how the material is received when deposited under the skin. This rig also allows manufacturers to determine the force required to withdraw the plunger from the syringe. The method enables syringe manufacturers and pharmaceutical companies to precisely quantify the performance of their products so that they are able to optimise usability and patient comfort, while guaranteeing quality control and product safety. The universal design allows a wide range of syringe types and sizes (from 5-50mm diameter) to be supported securely for testing.

Formulations are transferred into identical plastic syringes to a constant height. The content of each syringe is fully expressed using the Texture Analyser in compression mode and the resistance to expression is determined from the area under the resultant force-time plot. Increased work of syringeability is denoted by increased areas under the curves.

Universal Syringe Test Rig and assessment of force to expel syringe contents

Needle sharpness, which is an important characteristic for patient comfort, may be determined by a puncture test where the needle is held by a Tensile Grip on the Texture Analyser and is pushed through a standard substrate. The force required for insertion and extraction is measured.

Hypodermic Needle Testing and typical comparative graphs

Due to the challenging service environment that stents face in vivo, the radial stiffness of a stent is critical to its function of keeping the arteries open and eliminating abrupt closure or restenosis. Restenosis has been correlated with geometric properties of stents, such as the number of struts, the strut width and thickness, and the geometry of the cross section of each strut. A large number of stents with different geometric and mechanical features are available on the market. The therapeutic efficacy of stents depends largely on their mechanical properties, thereby influencing the choice of stents for treating specific tissues.

By performing texture analysis tests on the stents, researchers can improve design and performance. A compression test using a cylinder probe is the most common test to measure structural integrity.

The stent is positioned centrally under a cylinder probe and compressed to a chosen distance. During the test the force is shown to increase gradually as compression continues. The distances at 3 force values are recorded as measures of increasing stiffness.

Stent compression test and typical comparative graphs

For a full summary of typical texture analysis tests that can be performed on medical device products:

This information has been sourced, reviewed and adapted from materials provided by Stable Micro Systems Ltd.

For more information on this source, please visit Stable Micro Systems Ltd.

Read more here:
How to Measure the Physical Properties of Medical Devices - AZoM

HYDERABAD, India, Oct. 15, 2019 /PRNewswire/ -- LifeNet Health's Dermacell AWM, the world's most-advanced acellular dermal matrix (ADM) for wound treatment, is the first human ADM available in India. This introduction provides access to proven therapy for millions of patients in India suffering from chronic wounds.

Each year, as many as 100,000 patients in India face amputation due to a chronic wound. With more than 65 million people with diabetes and 7.5 million new cases diagnosed each year, the incidence of severe wounds and amputation is steadily increasing in India. Dermacell AWM has been shown to effectively treat challenging wounds, thereby reducing the threat of amputation and its debilitating impacts such as decreased quality of life and increased mortality.

"We are proud to offer Dermacell AWM as the first therapy of its kind in India," said Rony Thomas, President and CEO of LifeNet Health, a global leader in regenerative medicine. "It's a truly unique clinical solution to help patients overcome severe wounds and avoid the devastating effects of amputation."

Dermacell AWM has been utilized as an effective treatment in the U.S., the European Union and Latin America prior to its availability in India. It is supported by multiple studies that show it can bring serious wounds to complete resolution with fewer applications than conventional care or other graft materials. In a May 2019 clinical review, wounds treated with Dermacell AWM healed with an average of just one application, compared to an average of nine applications of an alternative material. A separate study published in September involving patients with large, complex Wagner grade 3 and 4 chronic wounds, including those with exposed bone showed Dermacell AWM helped heal or drastically reduce the size of the wounds within 16 weeks.

"Dermacell AWM has been rigorously studied in clinical settings and is supported by numerous peer-reviewed publications, including the largest-ever clinical trial of human ADMs for wound treatment," said Frederic Peycelon, LifeNet Health's Vice President of International Markets. "It is a powerful therapy that supports effective outcomes while also simplifying treatment by bringing wounds to closure in as little as one application."

LifeNet Health will feature Dermacell AWM at the VSICON Annual Conference Oct. 17-20 in Hyderabad, India. During the conference, Washington, D.C.-based clinician Zakee Shabazz, DPM, FACFAS, will present on his clinical experience with Dermacell AWM in the exhibit hall. Dr. Shabazz is board-certified in foot surgery and chief of podiatry at Innova Fair Oaks Hospital. A key opinion leader in his field, Dr. Shabazz has been focused for nearly 20 years on caring for patients with advanced podiatric techniques and technologies.

Dermacell AWM is backed by the technologies and relentless commitment to quality that have made LifeNet Health a global leader in regenerative medicine. LifeNet Health's rigorous screening and production processes ensure the safety and effectiveness of each graft, and patented Matracell decellularization technology. The result is a wound-treatment solution that offers unsurpassed efficacy with unrivaled safety.

About LifeNet HealthLifeNet Health helps save lives, restore health, and give hope to thousands each year. It is the world's most trusted provider of transplant solutions from organ procurement to bio-implants and cellular therapies and a leader in regenerative medicine, while always honoring the donors and healthcare professionals who enable healing. For more information about LifeNet Health, go to http://www.lifenethealth.org.

SOURCE LifeNet Health

http://www.LifeNetHealth.org

See the rest here:
LifeNet Health brings first clinically proven allograft-based biologic wound therapy to India - PRNewswire

DUBLIN--(BUSINESS WIRE)--The "United States Biobanks Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.

The country research report on United States biobanks market is a customer intelligence and competitive study of the United States market.

Moreover, the report provides deep insights into demand forecasts, market trends, and, micro and macro indicators in the United States market. Also, factors that are driving and restraining the biobanks market are highlighted in the study. This is an in-depth business intelligence report based on qualitative and quantitative parameters of the market.

Additionally, this report provides readers with market insights and detailed analysis of market segments to possible micro levels. The companies and dealers/distributors profiled in the report include manufacturers & suppliers of biobanks market in the United States.

Highlights of the report

The report provides detailed insights into:

1. Demand and supply conditions of biobanks market

2. Factor affecting the biobanks market in the short run and the long run

3. The dynamics including drivers, restraints, opportunities, political, socioeconomic factors, and technological factors

4. Key trends and future prospects

5. Leading companies operating in biobanks market and their competitive position in United States

6. The dealers/distributors profiles provide basic information of top 10 dealers & distributors operating in (United States) biobanks market

7. Matrix: to position the product types

8. Market estimates up to 2024

The report answers questions such as:

1. What is the market size of biobanks market in the United States?

2. What are the factors that affect the growth in biobanks market over the forecast period?

3. What is the competitive position in the United States biobanks market?

4. What are the opportunities in United States biobanks market?

5. What are the modes of entering United States biobanks market?

Key Topics Covered:

1. Report Overview

1.1. Report Description

1.2. Research Methods

1.3. Research Approaches

2. Executive Summary

3. Market Overview

3.1. Introduction

3.2. Market Dynamics

3.2.1. Drivers

3.2.2. Restraints

3.2.3. Opportunities

3.2.4. Challenges

3.3. PEST-Analysis

3.4. Porter's Diamond Model for United States Biobanks Market

3.5. Growth Matrix Analysis

3.6. Competitive Landscape in United States Biobanks Market

4. United States Biobanks Market by Products & Service

4.1. Equipment

4.2. Consumables

4.3. Services

4.4. Software

5. United States Biobanks Market by Sample Type

5.1. Blood Products

5.2. Human Tissues

5.3. Nucleic Acids

5.4. Cell Lines

5.5. Biological Fluids

5.6. Others

6. United States Biobanks Market by Application

6.1. Regenerative Medicine

6.2. Life Science Research

6.3. Clinical Research

7. Company Profiles

7.1. Manufacturer's & Suppliers

For more information about this report visit https://www.researchandmarkets.com/r/1phbdl

Read more:
United States Biobanks Market Prospects, Trends Analysis, Market Size and Forecasts 2019-2024 - ResearchAndMarkets.com - Business Wire

ORLANDO, Fla., Oct. 18, 2019 /PRNewswire-PRWeb/ -- The Laser Institute (LIA)'s 38th International Congress on Applications of Lasers & Electro-Optics (ICALEO) was recently held in Orlando, Florida and featured the conference's many firsts. A meeting of laser industry experts and decision-makers from around the world, the event hosted dialogue with a deeper industry foci, more expansive technical sessions, and a new Business Conference that addressed laser end-users while highlighting solutions from the manufacturing community.

A collection of Live User Solutions Forums, Market Drivers Symposia, and Live User Solutions Round Tables discussions, the Business Conference acted as a complement to ICALEO's traditional Technical Conference. Regarded as a concentrated effort of participants from the Aerospace, Biomedical, Microelectronics, and Automotive industries, ICALEO's Business sessions allowed laser manufacturers, integrators, and end-users to engage in the discussion on the unique challenges and revolutionary applications in the industry.

To further emphasize the attendee-friendly approach of this year's ICALEO format, the Business Conference also presented a four-day tradeshow that connected all members of the laser marketplace. An accomplishment at dedicating whole days to each of its selected industries, the tradeshow hosted over 40 international exhibitors from the likes of IPG Photonics, II-VI, and more.

Spanning the duration of the conference to maximize the attendee's opportunity to network with these leading brands, the assembly of exhibitors also included Han's Laser Smart Equipment Group (ICALEO's Diamond Sponsor), Coherent Inc. (ICALEO's Platinum Sponsor), as well as TRUMPF Inc., Kentek, and Edgewave (ICALEO's Gold Sponsors).

Meanwhile, the ICALEO Technical Conference enhanced its focus on the innovative and novel uses of lasers and photonics via its subdivided tracks. These are comprised of the Laser Additive Manufacturing, Laser Materials Macroprocessing, Laser Materials Microprocessing, Laser Nanomanufacturing, and Battery Systems and Energy Conversion tracks.

An approach that allowed the conference speakers to deliberate on how laser applications can push the envelope of modern technology while advancing key industries in their accuracy, efficiency, and speed, the Technical Conference's new format also gave engineers and materials processing experts the chance to discover new processing techniques, acquire new skills, and collaborate to ensure their organization stays up-to-date and on the leading edge of productivity.

These innovations and advancements were envisioned in the opening addresses of the plenary speakers from all four industries. Peter Boeijink of XYREC opened the aerospace-focused conference with his speech on "The Largest, Highest-Power, Mobile, Industrial, Laser Materials Processing Robot in the World" while Dr. Christoph Leyens from Fraunhofer IWS discussed the "Innovative Aerospace and Space Structures Made by Additive Manufacturing."

Similarly, the esteemed Professor William Steen presented his speech "The Coming of the Age of Optical Engineering" during the biomedical conference, alongside Fraunhofer Institute of Laser Technology (ILT)'s Dr. Nadine Nottrodt who spoke on "Laser in Biofabrication How Laser Technology Can Help to Build Artificial Tissue." They were joined by Dr. Chris Bashur of the Florida Institute of Technology who elaborated on the "Photonic Needs in Regenerative Medicine."

Participants from the microelectronics industry mulled over the words of Dr. Kumar Patel of Pranalytica Inc. during his plenary speech on "Recapturing the Excitement of High Power Infrared Lasers," while Dr. Markus Arendt of SUSS MicroTec Photonic Systems spoke on the "Excimer Laser Ablation for High-Density Routing in Advanced Packaging."

During the automotive-focused conference, Ethan Sprague from the University of Michigan presented his thoughts on "Laser Aided Manufacturing: Atom to Automobile" before Dr. Ted Reutzel of Pennsylvania State University described the "Progress Towards Sensing and Mitigating Flaw Formation in Powder Bed Fusion Additive Manufacturing." Their presentations joined the observations on "Bottoms Up Digital Design: The Quiet Revolution of the Additive Manufacturing Age" by Dr. Jason Carroll of Eaton, a power-management company that provides energy-efficient solutions to managing electrical, hydraulic, and mechanical power.

To view the highlighted content from ICALEO 2019, including recorded interviews, panels, and speeches, follow LIA's social media profiles on Facebook, Twitter, and LinkedIn. The 39th ICALEO will be held at the McCormick Place Convention Center in Chicago, Illinois USA from Oct 19, 2020Oct 22, 2020. Call for papers and Tradeshow booth bookings will be made available soon, and interested parties may contact icaleo@lia.org for further information.

SOURCE The Laser Institute

Here is the original post:
Future of Laser Innovations Reflected at Revamped ICALEO Conference - Benzinga

Post-mortem scans of injured brains are causing researchers to question the hypothesis that blunt force trauma from traumatic brain injuries (TBI) causes nerve damage.

The scans, conducted by a team including researchers at the New York-based Cold Spring Harbor Laboratory (CSHL), have shown greater signs of blood vessel damage than nerve damage, and could influence how drugs are developed and treatments are implemented for TBI.

CSHL professor Partha Mitra said: Nerve damage following traumatic brain injuries has been a majority point of view, and therapy as well as drug development has been targeted towards that.

The idea is that if the mechanism is actually different, therapeutic intervention may also be different.

The CSHL team performed close analysis on post-mortem brain tissue using a high-throughput neurohistological pipeline, an assemblage of techniques for labelling and visualising brain slices, which Mitra had developed to study mouse brains.

Scanning the brains in this way provides much clearer images than magnetic resonance imaging (MRI) alone. While MRI can show clinicians that brain damage has occurred, the resolution is limited and it can be hard to discern whether nerve or vascular injury has occurred.

Correlating neurohistological pipeline scanning with MRI scans allowed the team to see the vascular injuries more clearly.

The researchers focused on areas surrounding lesions where trauma had left a physical impact on the brain, which appeared on the MRI scans as black spots.

They then used an iron stain to test for the presence of blood and a myelin stain to test of the presence of nerve fibre fragments in the brain samples. While a significant amount of iron-marked stains appeared in the brain samples in these areas, indicating traumatic microbleeds in the tissue, the researchers did not find any significant nerve damage from the myelin stains.

The researchers concluded that traumatic vascular injury is distinct from nerve damage and could thus be a target for new therapies. They also found that these traumatic microbleeds could often predict future health problems and disabilities for people with TBI, although they could not determine their relationship with acute problems.

The study has been published in the neurology journal Brain.

The team now hopes to conduct research into the underlying causes and effects of TBI for better diagnosis, prognosis, therapeutic targets and patient outcomes.

CSHL worked with colleagues at the National Institutes of Health, National Institute of Neurological Disease and Stroke, University of Maryland, Center for Neuroscience and Regenerative Medicine, and Uniformed Services University of the Health Sciences, which had been studying the brains of deceased patients using MRI.

Enter your details here to receive your free whitepaper.

Close survey

Close

Read the original:
Nerve damage not the root cause for symptoms of traumatic brain injury - Medical Device Network